Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

UK study digs into CMV infection patterns in kidney transplant patients

NCT ID NCT06568055

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 330 kidney transplant patients in the UK to understand how cytomegalovirus (CMV) infections are managed. Researchers looked at how common these infections are, what treatments were used, and how well they worked. The goal was to gather information to improve future care, without changing any patient's treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

330 people

The number who actually took part.

Started

Sep 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with refractory CMV infection post-kidney transplant will be included. The reference cohort will include all participants identified to have responded to initial anti-CMV therapy post-transplant with no CMV which required the treatment of a 2nd anti-CMV agent during this episode of infection.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Refractory CMV group: 1. Participants aged greater than or equal to (\>=) 18 years at index date 2. Kidney transplant recipients on or subsequent to June 2016. 3. CMV viraemia or disease identified as requiring treatment and which was refractory to previous CMV management (at least one course of therapy), with or without confirmed resistance. 4. At least six months follow up time (except for participants who have died earlier). Reference cohort of non-refractory CMV group: 1. Participants aged \>=18 years. 2. Kidney transplant recipients. 3. Received initial CMV management (at least one course of therapy). 4. At least six months follow up time (except for participants who have died earlier). Exclusion Criteria: Refractory CMV group: 1. Multi-organ transplant recipients. 2. Participation recorded in an anti-CMV prophylaxis or treatment clinical trial from 2010 onward. Participants with non-refractory CMV are to be included as a reference to indicate impact of refractory CMV not responding to initial therapy on resource use and other outcomes. Reference cohort of non-refractory CMV group: 1. Multi-organ transplant recipients. 2. Participation recorded in an anti-CMV prophylaxis or treatment clinical trial from 2010. 3. CMV viremia or disease refractory to any previous anti-CMV therapy. 4. Treatment for CMV viremia or disease refractory to initial therapy during the follow up period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus (CMV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus (CMV)

Contacts and locations

Locations

  • RaDaR (part of the UK Kidney Association)

    Bristol, Southwestern England, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.